Oncology Brothers
@oncbrothers.bsky.social
Practice changing discussions by community oncologists: Drs. Rohit Gosain & Rahul Gosain. OwnViews/Not a Medical Advice.
COI http://bit.ly/3o9agL3
Web: http://oncbrothers.com
COI http://bit.ly/3o9agL3
Web: http://oncbrothers.com
Pinned
#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara
Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast
#gism #CanSky #OncSky
Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast
#gism #CanSky #OncSky
Reposted by Oncology Brothers
Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25
May 5, 2025 at 2:01 PM
Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25
Reposted by Oncology Brothers
Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy
Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches | JCO Oncology Advances
There have been significant advances in colorectal cancer (CRC) immunotherapy over
the past decade, with incorporation into both the metastatic and adjuvant/neoadjuvant
treatment spaces. However, ther...
ascopubs.org
April 17, 2025 at 4:09 PM
Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy
Reposted by Oncology Brothers
HER2 in NSCLC is underrecognized & complex. Grateful to join
@cor2edmeded.bsky.social
with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks
@oncbrothers.bsky.social
for the invite! #lcsm
#oncMedEd
cor2ed.com/lung-connect...
@cor2edmeded.bsky.social
with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks
@oncbrothers.bsky.social
for the invite! #lcsm
#oncMedEd
cor2ed.com/lung-connect...
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1 | COR2ED
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the
cor2ed.com
April 21, 2025 at 2:00 PM
HER2 in NSCLC is underrecognized & complex. Grateful to join
@cor2edmeded.bsky.social
with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks
@oncbrothers.bsky.social
for the invite! #lcsm
#oncMedEd
cor2ed.com/lung-connect...
@cor2edmeded.bsky.social
with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks
@oncbrothers.bsky.social
for the invite! #lcsm
#oncMedEd
cor2ed.com/lung-connect...
#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇)
Full 🗣️:
⭐️ Oncbrothers.com/cabinet
⭐️ Also on the “Oncology Brothers” podcast
#OncSky #MedSky #GiOnc
Full 🗣️:
⭐️ Oncbrothers.com/cabinet
⭐️ Also on the “Oncology Brothers” podcast
#OncSky #MedSky #GiOnc
April 10, 2025 at 10:02 PM
#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇)
Full 🗣️:
⭐️ Oncbrothers.com/cabinet
⭐️ Also on the “Oncology Brothers” podcast
#OncSky #MedSky #GiOnc
Full 🗣️:
⭐️ Oncbrothers.com/cabinet
⭐️ Also on the “Oncology Brothers” podcast
#OncSky #MedSky #GiOnc
Reposted by Oncology Brothers
I recently had the privilege of joining the @oncbrothers.bsky.social to discuss all things #PancreaticCancer, including current and emerging treatment options that are bringing hope for better outcomes for patients. Many thanks👊
oncbrothers.com/pancreatic-a...
www.cancernetwork.com/treatment-al...
oncbrothers.com/pancreatic-a...
www.cancernetwork.com/treatment-al...
April 8, 2025 at 9:27 PM
I recently had the privilege of joining the @oncbrothers.bsky.social to discuss all things #PancreaticCancer, including current and emerging treatment options that are bringing hope for better outcomes for patients. Many thanks👊
oncbrothers.com/pancreatic-a...
www.cancernetwork.com/treatment-al...
oncbrothers.com/pancreatic-a...
www.cancernetwork.com/treatment-al...
Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice!
⭐️ InPerson: May 31st, 2025
⭐️ Location📍Marriott Marquis
⭐️ Time: 6:30-9:00PM
⭐️ Register bit.ly/aioasco25
#AdvInOnc25 #OncSky
⭐️ InPerson: May 31st, 2025
⭐️ Location📍Marriott Marquis
⭐️ Time: 6:30-9:00PM
⭐️ Register bit.ly/aioasco25
#AdvInOnc25 #OncSky
April 7, 2025 at 2:23 AM
Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice!
⭐️ InPerson: May 31st, 2025
⭐️ Location📍Marriott Marquis
⭐️ Time: 6:30-9:00PM
⭐️ Register bit.ly/aioasco25
#AdvInOnc25 #OncSky
⭐️ InPerson: May 31st, 2025
⭐️ Location📍Marriott Marquis
⭐️ Time: 6:30-9:00PM
⭐️ Register bit.ly/aioasco25
#AdvInOnc25 #OncSky
#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara
Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast
#gism #CanSky #OncSky
Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast
#gism #CanSky #OncSky
February 22, 2025 at 4:34 PM
#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara
Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast
#gism #CanSky #OncSky
Full Discussion:
⭐️ Oncbrothers.com/zolbetuximab...
⭐️ Also on the “Oncology Brothers” podcast
#gism #CanSky #OncSky
Treatment Algorithm series: discussion on HER2+ #BreastCancer
✅ APT data/TCHP
✅ Metastatic disease
✅ Her2/ER/PR+
Full discussion:
⭐️ oncbrothers.com/her2positive...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #CancerSky #OncSky
@drsarahsammons.bsky.social
✅ APT data/TCHP
✅ Metastatic disease
✅ Her2/ER/PR+
Full discussion:
⭐️ oncbrothers.com/her2positive...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #CancerSky #OncSky
@drsarahsammons.bsky.social
February 18, 2025 at 2:16 AM
Treatment Algorithm series: discussion on HER2+ #BreastCancer
✅ APT data/TCHP
✅ Metastatic disease
✅ Her2/ER/PR+
Full discussion:
⭐️ oncbrothers.com/her2positive...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #CancerSky #OncSky
@drsarahsammons.bsky.social
✅ APT data/TCHP
✅ Metastatic disease
✅ Her2/ER/PR+
Full discussion:
⭐️ oncbrothers.com/her2positive...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #CancerSky #OncSky
@drsarahsammons.bsky.social
Reposted by Oncology Brothers
What is Dr. Brian Betts most excited about for #TANDEM25? 🥁
Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...
Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...
February 11, 2025 at 7:48 PM
What is Dr. Brian Betts most excited about for #TANDEM25? 🥁
Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...
Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...
Reposted by Oncology Brothers
Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...
Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers
In this statement, ASCO encourages academic medical centers to change their policies
and expectations to enhance and promote the professional fulfillment of academic medical
oncologists. The statement...
ascopubs.org
February 12, 2025 at 2:48 AM
Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...
Reposted by Oncology Brothers
As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
February 10, 2025 at 11:22 PM
As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social
✅ Early disease
✅ ≥T2 or N+ disease
✅ Metastatic disease
✅ Low ER/PR+
Full 🗣️:
⭐️ oncbrothers.com/how-to-treat...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #BreastCancer
✅ Early disease
✅ ≥T2 or N+ disease
✅ Metastatic disease
✅ Low ER/PR+
Full 🗣️:
⭐️ oncbrothers.com/how-to-treat...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #BreastCancer
February 11, 2025 at 12:31 AM
Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social
✅ Early disease
✅ ≥T2 or N+ disease
✅ Metastatic disease
✅ Low ER/PR+
Full 🗣️:
⭐️ oncbrothers.com/how-to-treat...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #BreastCancer
✅ Early disease
✅ ≥T2 or N+ disease
✅ Metastatic disease
✅ Low ER/PR+
Full 🗣️:
⭐️ oncbrothers.com/how-to-treat...
⭐️ www.cancernetwork.com/treatment-al...
⭐️ “Oncology Brothers” podcast
#bcsm #BreastCancer
Reposted by Oncology Brothers
The #GU25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GU cancers here: brnw.ch/21wQBxm
Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology
Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology
February 10, 2025 at 10:41 PM
The #GU25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GU cancers here: brnw.ch/21wQBxm
Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology
Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology
🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
February 6, 2025 at 11:23 PM
🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
AMPLIFY for 1L CLL now in @nejm.org
🔑 takeaways:
1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem)
2️⃣ AVO showed deeper responses but higher infection risk
3️⃣ New SoC for many
#OncSky #CanSky #HemeSky
🔑 takeaways:
1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem)
2️⃣ AVO showed deeper responses but higher infection risk
3️⃣ New SoC for many
#OncSky #CanSky #HemeSky
February 6, 2025 at 2:55 AM
AMPLIFY for 1L CLL now in @nejm.org
🔑 takeaways:
1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem)
2️⃣ AVO showed deeper responses but higher infection risk
3️⃣ New SoC for many
#OncSky #CanSky #HemeSky
🔑 takeaways:
1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem)
2️⃣ AVO showed deeper responses but higher infection risk
3️⃣ New SoC for many
#OncSky #CanSky #HemeSky
Reposted by Oncology Brothers
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
February 3, 2025 at 11:48 AM
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
Reposted by Oncology Brothers
Nice discussion on management of intermediate risk #HCC hosted by @oncbrothers.bsky.social!
Cc: @markyarchoan.bsky.social
#liversky #oncsky
oncbrothers.com/liver-2024-4
Cc: @markyarchoan.bsky.social
#liversky #oncsky
oncbrothers.com/liver-2024-4
Intermediate HCC – the evolving role of Immunotherapy with Multimodality approaches
oncbrothers.com
January 27, 2025 at 10:10 PM
Nice discussion on management of intermediate risk #HCC hosted by @oncbrothers.bsky.social!
Cc: @markyarchoan.bsky.social
#liversky #oncsky
oncbrothers.com/liver-2024-4
Cc: @markyarchoan.bsky.social
#liversky #oncsky
oncbrothers.com/liver-2024-4
Reposted by Oncology Brothers
T-DXd approved today after progression on CDK4/6 inhibitor for HR+ HER2-low and HER2-ultralow metastatic breast cancer based on results of DESTINY-Breast06. #bcsm #oncsky
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com
January 28, 2025 at 12:50 AM
Reposted by Oncology Brothers
T-Dxd approved as first line chemo in HR+, HER2 low or ultra low disease.
Do all patients need it first line?
Probably not. But great option for higher risk.
#bcsm #oncosky
Do all patients need it first line?
Probably not. But great option for higher risk.
#bcsm #oncosky
📌 Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com/media-centre...
@oncoalert.bsky.social
www.astrazeneca.com/media-centre...
@oncoalert.bsky.social
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com
January 28, 2025 at 12:51 AM
Reposted by Oncology Brothers
🔥🔥🔥BREAKWATER🔥🔥🔥
BRAF V600E mut #CRC
SOC (FOLFOX) +/- encorafenib + cetuximab
EC + FOLFOX shows:
✅⬆️ORR
✅Strong suggestion of ⬆️OS
🚨EC + FOLFOX is a new SOC‼️
Pub available: idp.nature.com/authorize?re...
#GI25 @ascocancer.bsky.social
BRAF V600E mut #CRC
SOC (FOLFOX) +/- encorafenib + cetuximab
EC + FOLFOX shows:
✅⬆️ORR
✅Strong suggestion of ⬆️OS
🚨EC + FOLFOX is a new SOC‼️
Pub available: idp.nature.com/authorize?re...
#GI25 @ascocancer.bsky.social
January 25, 2025 at 11:11 PM
🔥🔥🔥BREAKWATER🔥🔥🔥
BRAF V600E mut #CRC
SOC (FOLFOX) +/- encorafenib + cetuximab
EC + FOLFOX shows:
✅⬆️ORR
✅Strong suggestion of ⬆️OS
🚨EC + FOLFOX is a new SOC‼️
Pub available: idp.nature.com/authorize?re...
#GI25 @ascocancer.bsky.social
BRAF V600E mut #CRC
SOC (FOLFOX) +/- encorafenib + cetuximab
EC + FOLFOX shows:
✅⬆️ORR
✅Strong suggestion of ⬆️OS
🚨EC + FOLFOX is a new SOC‼️
Pub available: idp.nature.com/authorize?re...
#GI25 @ascocancer.bsky.social
#GI25 highlights #CommunityOnc:
1. #SCIENCE: Adv Eso SCC
2. #ESOPEC publication (Eso/GEJ/Ga)
3. Chemo in resectable Panc Ca
4. #StarterNET: GEP-NET
5. #CM8HW: dMMR/MSI-H mCRC
6. #BREAKWATER: BRAFV600E mCRC
7. ctDNA: #BESPOKE + SWOG80702
#OncSky #gism @ascocancer.bsky.social
1/8
1. #SCIENCE: Adv Eso SCC
2. #ESOPEC publication (Eso/GEJ/Ga)
3. Chemo in resectable Panc Ca
4. #StarterNET: GEP-NET
5. #CM8HW: dMMR/MSI-H mCRC
6. #BREAKWATER: BRAFV600E mCRC
7. ctDNA: #BESPOKE + SWOG80702
#OncSky #gism @ascocancer.bsky.social
1/8
January 25, 2025 at 11:12 PM
#GI25 highlights #CommunityOnc:
1. #SCIENCE: Adv Eso SCC
2. #ESOPEC publication (Eso/GEJ/Ga)
3. Chemo in resectable Panc Ca
4. #StarterNET: GEP-NET
5. #CM8HW: dMMR/MSI-H mCRC
6. #BREAKWATER: BRAFV600E mCRC
7. ctDNA: #BESPOKE + SWOG80702
#OncSky #gism @ascocancer.bsky.social
1/8
1. #SCIENCE: Adv Eso SCC
2. #ESOPEC publication (Eso/GEJ/Ga)
3. Chemo in resectable Panc Ca
4. #StarterNET: GEP-NET
5. #CM8HW: dMMR/MSI-H mCRC
6. #BREAKWATER: BRAFV600E mCRC
7. ctDNA: #BESPOKE + SWOG80702
#OncSky #gism @ascocancer.bsky.social
1/8
Reposted by Oncology Brothers
Join us for Intersections: Personalized Risk Assessment for Gastrointestinal Cancers with Mary Uan-Sian Feng, MD. Gain insights on risk scores, biomarkers for screening, and more cutting-edge updates at #GI25!
January 24, 2025 at 4:58 PM
Join us for Intersections: Personalized Risk Assessment for Gastrointestinal Cancers with Mary Uan-Sian Feng, MD. Gain insights on risk scores, biomarkers for screening, and more cutting-edge updates at #GI25!
Reposted by Oncology Brothers
5/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 2👩⚕️
Pt characteristics in INAVO120:
No prior treatment for ABC
PIK3CA mut
a1c≤6.0, fasting BG<126
~Half with ≥3 involved organ sites
~Half with liver involvement, ~40% with 🫁 involvement
~1/3 with 1° endocrine resistance, 2/3 with 2°
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 2👩⚕️
Pt characteristics in INAVO120:
No prior treatment for ABC
PIK3CA mut
a1c≤6.0, fasting BG<126
~Half with ≥3 involved organ sites
~Half with liver involvement, ~40% with 🫁 involvement
~1/3 with 1° endocrine resistance, 2/3 with 2°
@dr-rshatsky.bsky.social
January 15, 2025 at 1:18 AM
5/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 2👩⚕️
Pt characteristics in INAVO120:
No prior treatment for ABC
PIK3CA mut
a1c≤6.0, fasting BG<126
~Half with ≥3 involved organ sites
~Half with liver involvement, ~40% with 🫁 involvement
~1/3 with 1° endocrine resistance, 2/3 with 2°
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 2👩⚕️
Pt characteristics in INAVO120:
No prior treatment for ABC
PIK3CA mut
a1c≤6.0, fasting BG<126
~Half with ≥3 involved organ sites
~Half with liver involvement, ~40% with 🫁 involvement
~1/3 with 1° endocrine resistance, 2/3 with 2°
@dr-rshatsky.bsky.social